Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application
Dai ChuanYun, Fu Ya, Chen ShaoCheng, Li Biao, Yao Bo, Liu WanHong, Zhu LiQing, Chen Nan, Chen Ji, Zhang Qiang.Sci China Life Sci (2013), Vol. 56, pages 51-58
Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results
Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA.J Clin Oncol (2013) Jan 22
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours
Zucali PA, Simonelli M, De Vincenzo F, Lorenzi E, Perrino M, Bertossi M, Finotto R, Naimo S, Balzarini L, Bonifacio C, Timofeeva I, Rossoni G, Mazzola G, Lambiase A, Bordignon C, Santoro A.Br J Cancer (2013), Vol. 108, pages 58-63
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation
Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE.Ann Oncol (2012) Oct 26.
Systemic TNFα Gene Therapy Synergizes With Liposomal Doxorubicine in the Treatment of Metastatic Cancer
Su B, Cengizeroglu A, Farkasova K, Viola JR, Anton M, Ellwart JW, Haase R, Wagner E, Ogris M.Mol Ther (2012) Nov 13. doi: 10.1038/mt.2012.229.
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
Lorusso D, Scambia G, Amadio G, di Legge A, Pietragalla A, De Vincenzo R, Masciullo V, Di Stefano M, Mangili G, Citterio G, Mantori M, Lambiase A, Bordignon C.Br J Cancer (2012), Vol.107, pages 37-42
Effect of tumour necrosis factor-alpha on estrogen metabolic pathways in breast cancer cells
Kamel M, Shouman S, El-Merzebany M, Kilic G, Veenstra T, Saeed M, Wagih M, Diaz-Arrastia C, Patel D, Salama S.J Cancer (2012), Vol.3, pages 310-21
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies
Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, Guglielmi A, Pessino A, Sciallero S, Sobrero AF, Mazzola G, Lambiase A, Bordignon C.Ann Oncol (2011), Vol.22, pages 973-8
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C.Br J Cancer (2010), Vol.103, pages 837-44
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy
Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C.Eur J Cancer (2010), Vol.46, pages 2746-52
TNFalpha gene delivery therapy for solid tumors
Hernandez J, Cooper J, Babel N, Morton C, Rosemurgy AS.Expert Opin Biol Ther (2010), Vol.10, pages 993-9
Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand
Chae SY, Kim TH, Park K, Jin CH, Son S, Lee S, Youn YS, Kim K, Jo DG, Kwon IC, Chen X, Lee KC.Mol Cancer Ther. (2010), Vol.9, pages 1719-29
Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation
Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ 3rd, Kraft SL, Gustafson DL, Vail DM.Clin Cancer Res (2010), Vol.16, pages 1498-508
Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor
Meany HJ, Seibel NL, Sun J, Finklestein JZ, Sato J, Kelleher J, Sondel P, Reaman G.J Immunother (2008), Vol.31, pages 679-83
TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility
R. van Horssen, T.L.M. ten Hagen and A.M.M. EggermontThe Oncologist (2006), Vol. 11 pages 397-408
Functionalization of tumor necrosis factor-α using phage display technique and PEGylation improves its antitumor therapeutic window
H. Shibata, Y. Yoshioka, S. Ikemizu, K. Kobayashi, Y. Yamamoto, Y. Mukai, T. Okamoto, M. Taniai, M. Kawamura, Y. Abe, S. Nakagawa, T. Hayakawa, S. Nagata, Y. Yamagata, T. Mayumi, H. Kamada and Y. TsutsumiClinical Cancer Research (2004), Vol. 10 pages 8293-8300
Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency
Yoshioka Y, Tsutsumi Y, Ikemizu S, Yamamoto Y, Shibata H, Nishibata T, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Nagata S, Yamagata Y, Mayumi T.Biochem Biophys Res Commun. (2004), Vol.315, pages 808-14
Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-α: a novel polymer-conjugation technique with a reversible amino-protective reagent
S. Tsunoda, T. Ishikawa, Y. Yamamoto, H. Kamada, K. Koizumi, J. Matsui, Y. Tsutsumi, T. Hirano and T. MayumiJournal of Pharmacology and Experimental Therapeutics (1999), Vol. 290 pages 368-372
Molecular design of hybrid tumor necrosis factor-α III: polyethylene glycol-modified tumor necrosis factor-α has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation
Y. Tsutsumi, T. Kihira, S. Tsunoda, H. Kamada, S. Nakagawa, Y. Kaneda, T. Kanamori and T. MayumiJournal of Pharmacology and Experimental Therapeutics (1999), Vol. 278 pages 1006-1011
In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-α against tumor necrosis factor resistant tumors
Y. Tsutsumi, S. Tsunoda, Y. Kaneda, H. Kamada, T. Kihira, S. Nakagawa, Y. Yamamoto, Y. Horisawa and T. MayumiJapanese Journal of Cancer Research (1996), Vol. 87 pages 1078-1085
Molecular design of hybrid tumour necrosis factor α with polyethylene glycol increases its anti-tumour potency
Y. Tsutsumi, T. Kihira, S. Tsunoda, T. Kanamori, S. Nakagawa and T. MayumiBritish Journal of Cancer (1995), Vol. 71 pages 963-968
Intravenous administration of polyethylene glycol-modified tumor necrosis factor-α completely regressed solid tumor in Meth-A murine sarcoma model
Y. Tsutsumi, T. Kihira, S. Tsunoda, K. Kubo, M. Miyake, T. Kanamori, S. Nakagawa and T. MayumiJapanese Journal of Cancer Research (1994), Vol. 85 pages 1185-1188.
Chemical modification of natural human tumor necrosis factor-α with polyethylene glycol increases its anti-tumor potency
Y. Tsutsumi, T. Kihira, S. Yamamoto K. Kubo, S. Nakagawa, M. Miyake, Y. Horisawa, T. Kanamori, H. Ikegami and T, MayumiJapanese Journal of Cancer Research (1994), Vol. 85 pages 9-12
Tumour necrosis factor in man: clinical and biological observations
P. Selby, S. Hobbs, C. Viner, E. Jackson, A. Jones, D. Newell, A.H. Calvert, T. McElwain, K. Fearon and J. HumphreysBritish Journal of Cancer (1987), Vol. 56 pages 803-808
Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice
K. Haranaka, N. Satomi and A. SakuraiInternational Journal of Cancer (1984), Vol. 34 pages 263-267
An endotoxin-induced serum factor that causes necrosis of tumors
E.A. Carswell, L.J. Old, R.L. Kassel, S. Green, N. Fiore and B.D. WilliamsonProceedings of the National Academy of Sciences (1975), Vol. 72 pages 3666-3670